HYTN Innovations has entered into strategic supply agreements and successfully completed vendor qualification with two cannabis cultivators under its Good Manufacturing Practice system qualifying a minimum of 4000 kg of cannabis for the German market.
The Agreements, which were entered into in February 2025, were subject to HYTN's qualification process through which the Company conducted site audits, quality control evaluations, and verified compliance with Good Agricultural and Collection Practices (GACP) to ensure alignment with German pharmacopeia standards. These Agreements establish strict product specifications, testing protocols, and pricing structures, ensuring compliance with stringent microbiological limits and non-irradiation requirements while securing a reliable and consistent cannabis supply for Germany. The two cultivators that have been qualified in HYTN's system for the German market are Klonetics Plant Science Inc. and another Kelowna company that has requested non-disclosure.
With qualification complete, the approved cultivators will commence production, focusing on high-potency cultivars specifically tailored for German patient needs HYTN's GMP-certification ensures that all cannabis destined for Germany will adhere to the highest pharmaceutical standards, meeting the country's exacting regulatory requirements.
"With global demand for GMP-certified cannabis increasing, HYTN remains committed to partnering with the most qualified cultivators to ensure seamless integration into international medical markets," said Jason Broome, HYTN Chief Operating Officer. He added, "We are proud to support patient access to premium medical cannabis in Germany and look forward to establishing HYTN as a preferred partner for pharmaceutical-grade cannabis in Europe."
For more information:
HYTN Innovations
hytn.ca/